Biweekly Gemcitabine, Doxorubicin, and Paclitaxel as First-Line Treatment in Metastatic Breast Cancer
ByPedro Sánchez-Rovira, MD, PhD,Ana Jaén, MD,Encarna González, MD,Ignacio Porras, MD,Rosario Dueñas, MD,Begoña Medina, MD,Nicolás Mohedano, MD,Margarita Fernández, MD,Maximiliano Martos, MD,Ana Lozano, MD,Eva Carrasco, MD
Published: | Updated:
In a single-center, open, phase II trial, we assessed the toxicity and activity of a triple combination therapy-doxorubicin at 30 mg/m2 (day 1), paclitaxel (Taxol) at 135 mg/m2 (day 2), and gemcitabine (Gemzar) at 2,500 mg/m2